Hoping we get a planned phase3 against ABSSSI going since B saw good success in phase2. We'll see.

I imagine many saddened hearts here myself included. Good luck and peace be with you.

Yep B got sent packing. The lab testing was beautiful oh well.

BP got in early approval with milds which put us in the war zone... we end in a disappointing failure. Anyway it's done disappointing as it is.

Covid put much needed money in IPIX bank acct, I agree more on B to come. Get phase 3 going Leo sheesh.

Thanks for posting this.

I really thought we'd see some positive results in the moderates if we got any. Hopefully we can now get back on track.

Man that was a tough hit, I'm bloody red. Lets see what UC does.

Great post going into data release. Where's there's smoke there's fire right.

My guess we are looking for moderates with a high viral load to have strong results. I'm thinking B's strong suite. We are where the rubber meets the road now.

Yeah Leo could report he's reviewing the great data. More to come Monday:)

The potential is HUGE. antibacterial, antiviral, anti-inflammatory all rolled into one.
Then there's biofilm studies plus this goodie- "A key aspect of Brilacidin's mechanism of action, inhibiting Phosphodiesterase 4 (PDE4), may further support its use in treating other chronic autoimmune conditions". Chronic immune problems encompasses a large swath of the population. Go B

"Company’s biostatistics vendor" is currently engaged. It's pretty much in Leo's hands now perhaps he's getting good updates as they go through it.

Hmmm need more insight from poster.

Something in the works? I did not find it referenced.

Words have no effect on Leo or this trial. Just need results no stopping B now.

Exactly my thought. Possibly Leo has gotten positive feedback. Looking for a mega pr now.

Per 10Q- The Company has received individual patient Expanded Access (compassionate use) requests for Brilacidin to treat critically ill COVID-19 patients who are not responding to prior therapy. Expanded Access was implemented by the FDA and Congress to address physician applications for access to potentially lifesaving drugs, prior to FDA approval, for patients in their care when available treatment options have failed. Following receipt of such requests, the Company has supplied Brilacidin to relevant hospitals for individual patient use, with the FDA granting the treating physician permission for the emergency administration of Brilacidin.



The Phase 2 COVID-19 clinical trial data as of the date of this Form 10-Q remains blinded to the Company. The Company’s biostatistics vendor is currently engaged in analyzing and computing study data and they are expected to deliver Topline results to the Company during the second week of November, 2021.

Topline results still on for this week.

They've shown to be very synergistic and now this trial would clinch it. I could see a Gilead offer.

I hope there's extra gravy.

Clock is counting down ipix news at anytime.

Feels like waiting on our reprieve call from the governor. Leo don't wait till 11:59, let the good news rip.

Amen brother. Success in moderate would help end the most severe cases.imo

Brilacidin has a stellar track record in past clinical trials.

Yes it's prerevenue with some skiddish investors and the ones who prey on that.

Thanks,, data lock just means no one can add or take away, when unblinded it's ready for all to view.

I believe the contacts have all been made and Leo has gone as far as he can prior to receiving data release. That email pretty much summed that up.

"We look forward to learning about our trial results anticipated to be unblinded and reported this week".

Very good to hear that. Many thanks for your effort today DrBones.

yep, thanks,,Seems B's MOA keeps growing.

Great read. I love these new findings. "heparin sulfate proteoglycans are found in number of viruses which means Brilaidin may be effective as an antiviral against more viral strains than previously thought".

Wow great work! Thanks.

Dr Degrado's study states that B binds to heparan sulfate proteoglycans (HSPGs) This result suggests that brilacidin has an additional mechanism of action by binding to HSPGs on the host cell, thereby blocking viral attachment. So not only does B disrupt the viral envelopes integrity it also binds to HSPGs leaving the virus to fail. Stopping the virus two ways. So more of B's MOA has been discovered and released. My take as I read the findings.

These viruses are responsible for the common cold. Nice to see B's robust response to them. A chest cold hospitalizes a lot of people. Many thanks Dr Bones for original posting.

This also from Reuters- Russia's daily COVID-19 death toll hits record high
https://news.yahoo.com/russias-daily-covid-19-death-080746509.html?fr=sycsrp_catchall

No after hours pr today. My theory is any news before Friday would likely be good news.. Keep checking those inboxes.

Yep what a coincidence..

Yep. We need cover hopefully Leo's holding the shotgun.

Then there's this "Study shows dramatic decline in effectiveness of all three COVID-19 vaccines over time"
Phizer is the real insider. Go little B make us proud.

https://www.yahoo.com/news/study-shows-dramatic-decline-effectiveness-025801001.html

Pr said Week of the eighth.

That big Phizer covid banner called today's action.